Probiotics as anti-infective agents:  Probiotics-based adjunct therapy for viral and bacterial infections: Probiotic Lactococcus lactis ssp.Lactis JCM5805 inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the antiviral Proteins IFITM3, & Interferon-stimulated gene, 19/March/2019, 6.34 am

Hydrogen gas inhalation therapy for Cardiomyopathy: Inhalation of Hydrogen gas decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins, and alleviates Cardiomyopathy, via up regulation of its target gene, 19/March/2019, 6.23 am
March 19, 2019
Ribonucleic acid-based therapy for Diabetes: LncRNA C2dat1 increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 19/March/2019, 6.49 am
March 19, 2019
Show all

Introduction: What they say:

A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33),  by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Probiotics as anti-infective agents:  Probiotics-based adjunct therapy for viral and bacterial infections: Probiotic Lactococcus lactis ssp.Lactis JCM5805 inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the antiviral Proteins IFITM3, & Interferon-stimulated gene


What is known?

Prof. Stephen Elledge research team has shown that interferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that Probiotic Lactococcus lactis ssp.Lactis JCM5805, by decreasing the expression of its target genes, it may increase the expression of interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2, and antimicrobial peptides. Thereby, it may: (1) inhibit the replication of  Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses; (2) confer resistance against  infection caused by Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses; and (3) promote innate immunity (Figure 1) Thus, pharmacological formulations encompassing “Probiotic Lactococcus lactis ssp.Lactis JCM5805, either alone or in combination with other drugs,” may be used to prevent/treat infections caused by Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses (Figure 2).

Figure 1. Mechanistic insight into how Probiotic Lactococcus lactis ssp.Lactis JCM5805 inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial, Sindbis, and SFV viruses production. Probiotic Lactobacillus rhamnosus (EE) functions as a broad-spectrum anti-infective agent through induction of its target genes, such as antiviral Proteins IFITM3, Interferon-stimulated gene 15, & Mx2

Figure 2. Probiotic Lactococcus lactis ssp.Lactis JCM5805 may function as a broad-spectrum anti-infective agent through induction of antiviral proteins, such as IFITM3, Interferon-stimulated gene 15, & Mx2.


Details of the research findings: 

Idea formulated by Dr L Boominathan PhD

Undisclosed information: How Probiotic Lactococcus lactis ssp.Lactis JCM5805 increases the expression of Antiviral Protein IFITM3, Interferon-stimulated gene 15, & Mx2

Amount: $ 500#

# Research cooperation

For more details on payment, you may reach us at admin@genomediscovery.org


References: 

CitationBoominathan L, Probiotics as anti-infective agents:  Probiotics-based adjunct therapy for viral and bacterial infections: Probiotic Lactococcus lactis ssp.Lactis JCM5805 inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the antiviral Proteins IFITM3, & Interferon-stimulated gene, 19/March/2019, 6.34 am


Courtesy:
 When you cite drop us a line at info@genomediscovery.org,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Comments are closed.